New vaccine fights placental malaria
The vaccine uses ExpreS2ion’s proprietary protein expression technology called ExpreS3 to carry the malaria antigen into the body. It has taken many years of research to reach this point, and the new vaccine will soon be ready for testing in humans.
“This is a very important milestone for our company,” ExpreS2ion Biotechnologies CEO Charlotte Dyring said. “The ExpreS2 system solved the protein expression challenge for this antigen that had failed to be expressed in alternative systems. More than 30 variants of the complex malaria antigen that forms part of this vaccine were produced by ExpreS2ion to enable Professor (Ali) Salanti’s team to perform the needed tests to select the most promising vaccine candidate. A very robust production process for the antigen was developed by ExpreS2ion and transferred to a manufacturer for production of a batch performed under conditions necessary for human testing."
Dyring said she considers the collaboration with the University of Copenhagen an important success, reflecting their delivery on the needs of the project and demonstration of their product's ability to seamlessly deliver results from research to manufacturing.
“It is the first time that a university in Denmark has conceived and produced a vaccine, and this has only been achieved because of the very close cooperation within the consortium that includes ExpreS2ion and the University,” Salanti said.